Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Advanced intelligence and close-loop control for Crystallisation of API’s (Active Pharmaceutical Ingredients)

Project description

New tool could revolutionise the development of medicine

Ensuring a consistent supply of high-quality active pharmaceutical ingredients (APIs) is the cornerstone of the pharmaceutical industry. High-quality APIs require consistent physical and chemical properties from batch to batch. These properties directly influence both the quality and safety of the final drug product and are therefore critical to efficacious patient therapy. Around 80 % of the world's APIs are dependent on crystallisation, which is a complex process that requires continuous monitoring to reach optimal quality with minimal waste. To address these challenges, the EU-funded SmartCrys project is supporting Innopharma Labs Limited in developing a fully vertically integrated manufacturing intelligence platform for crystallisation unit operations. The SmartCrys analyser suite is integrated with data storage and analytics capabilities to enable real-time remote monitoring and process automation control.

Objective

The project aims to address key challenges of the pharmaceutical industry related to the consistent supply of active pharmaceutical ingredients (APIs) which are formed through crystallisation processes. Over 80% of the worlds API’s have crystallisation steps. The current method of determining process performance is a combination of off-line analysis of the quality attributes of the API crystals after the crystallisation process is complete. This methodology does not control the manufacturing process and leads to a variable quality product, variable yields and a large proportion of rework batches, costing the API industry in excess of €10B/year. SmartCrys is an integrated solution for API processing issues of (1) in-line PAT Analysers to measure the critical quality attributes of the crystals, (2) Manufacturing Intelligence to interpret the data and decide whether process adjustments are required, (3) Process Automation which enable the automatic adjustment of the process to take place and (4) Data Analytics which enable visibility of all process data in real-time. SmartCrys enables rapid process development and subsequently self-adjustment of crystallization processes in real time, targeting an addressable market for SmartCrys of €20B. Through engagement with its customer base (8 of the top 10 Pharma companies worldwide) and the regulators, Innopharma have identified a technological gap in in-line process control among API manufacturers. SmartCrys will consolidate Innopharma’s position as one of the world’s leaders in Advanced Analytical Technologies within the pharmaceutical sector, and provide an opportunity to increase company turnover from €8M to €23M over the next 5 years and to grow staff from 45 to 65. It will also contribute to the continued competitiveness of the European API crystallization sector and help retain thousands of high-tech API manufacturing jobs within Europe.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

INNOPHARMA LABS LIMITED
Net EU contribution
€ 1 610 875,00
Address
ASHFIELD CRONE LOWER
Y14 REDCROSS
Ireland
SME
Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 301 250,00